The registry identifies progression-free survival as the primary endpoint and describes a randomized, parallel-group phase 2 comparison of palbociclib plus endocrine therapy versus endocrine therapy. The registry does not report posted statistical analyses for the primary endpoint.
1. Trial at a Glance
PALMIRA is a randomized phase 2 trial in advanced breast cancer evaluating whether continuation of palbociclib with second-line endocrine therapy can be assessed against endocrine therapy alone in pre- and post-menopausal women with hormone receptor-positive/HER2-negative disease.
| Feature | PALMIRA |
|---|---|
| Trial acronym | PALMIRA |
| NCT identifier | NCT03809988 |
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrollment | 198 |
| Allocation | RANDOMIZED |
| Design model | PARALLEL |
| Masking | NONE |
| Primary purpose | TREATMENT |
| Number of arms | 2 |
| Lead sponsor | MedSIR |
| Sponsor type | OTHER |
2. Clinical Question
The central clinical question is whether continuation of palbociclib treatment combined with second-line endocrine therapy produces a different progression-free survival experience than endocrine therapy alone in pre- and post-menopausal women with hormone receptor-positive/HER2-negative advanced breast cancer.
Population
Pre- and post-menopausal women with HR-positive/HER2-negative advanced breast cancer, as described in the primary endpoint definition.
Intervention
Continuation of palbociclib treatment combined with second-line endocrine therapy.
Comparator
Endocrine therapy.
Primary question
How does progression-free survival compare between continuation of palbociclib with second-line endocrine therapy and endocrine therapy alone?
3. Trial Design
Palbociclib + endocrine therapy
- Continuation of palbociclib treatment
- Second-line endocrine therapy
Endocrine therapy
- Endocrine therapy
The registry identifies the endocrine therapies used in the primary endpoint description as letrozole or fulvestrant. The registered intervention list identifies palbociclib and endocrine therapy as the study interventions.
Study timeline
Study start
The registered study start date was April 5, 2019.
Primary completion
The registered primary completion date was November 30, 2022.
4. Endpoints
| Endpoint | Time frame | Registry definition |
|---|---|---|
| PFS (Progression-free survival) | Baseline up to 29 months | From randomization until objective tumor progression or death, assessed by RECIST criteria v.1.1. |
The primary endpoint is therefore a time-to-event endpoint. Each participant can contribute follow-up until one of the defined events occurs or until the participant is no longer observed under the endpoint's follow-up framework.
What PFS measures
Progression-free survival combines two possible events into a single endpoint: objective tumor progression or death. The time origin is randomization, so the endpoint compares the time-to-event experience beginning at the point when treatment assignment occurs.
The registry specifies RECIST criteria v.1.1 for assessment of objective tumor progression and defines the primary endpoint time frame as baseline up to 29 months.
5. Planned Analysis
The registry identifies PFS as the primary endpoint but does not post a statistical analysis for it. Results have not been posted on ClinicalTrials.gov.
How PFS is typically analysed
For a randomized trial with progression-free survival as the primary endpoint, the usual statistical framework is a time-to-event analysis. Kaplan-Meier estimation is commonly used to describe the PFS distribution over time, while a log-rank test can be used to compare randomized groups. A Cox proportional-hazards model is commonly used to estimate a hazard ratio and its confidence interval.
Kaplan-Meier analysis
The Kaplan-Meier estimator describes the estimated probability of remaining progression-free over follow-up while accounting for right-censored observations.
Hazard ratio
A Cox model can summarize the relative instantaneous event rate between randomized groups, provided the model assumptions are appropriate.
Log-rank comparison
A log-rank test can compare the observed time-to-event distributions between the randomized treatment groups.
RECIST assessment
The registry specifies RECIST criteria v.1.1 for determining objective tumor progression, which supplies the event definition used in PFS.
6. Statistical Methodology
Time-to-event analysis
PFS is fundamentally different from a simple binary endpoint such as the proportion of participants who progressed by a fixed date. It records when the first qualifying event occurs. Participants who have not experienced progression or death during observed follow-up can still contribute information through their last known event-free time.
Here, di represents the number of events at event time ti, while ni represents the number at risk immediately before that time.
For PALMIRA, the event definition is especially important because PFS ends at either objective tumor progression or death. The statistical analysis must therefore preserve both components of the endpoint rather than treating progression alone as the complete event definition.
Censoring
Time-to-event methods can incorporate participants whose qualifying event has not been observed during their available follow-up. Such observations are typically right-censored at the appropriate analysis time. The validity of the resulting survival estimates depends on the assumptions governing censoring and follow-up.
Hazard ratios
A Cox proportional-hazards model is a standard approach for estimating a relative treatment effect for PFS. The hazard ratio compares the estimated instantaneous event rates between groups within the model rather than comparing the proportions of patients who eventually experience progression or death.
A hazard ratio is a relative time-to-event measure. It is not a median, a probability of cure, a relative risk, or a direct statement about the outcome of every individual participant.
Randomization and causal comparison
Randomization is central to the design because treatment assignment occurs before the comparative outcome is observed. When the randomized comparison is analysed according to the assigned groups, randomization provides the principal basis for attributing systematic differences in outcomes to treatment rather than to measured or unmeasured baseline characteristics.
RECIST-defined progression
The registry specifies RECIST criteria v.1.1 for objective tumor progression. This is statistically important because the endpoint depends not only on the timing of follow-up but also on a standardized rule for deciding when progression has occurred.
7. Statistical Methods Explained
Why is PFS a time-to-event endpoint?
Because PALMIRA defines PFS as the period from randomization until objective tumor progression or death, the timing of the event matters. A participant progressing early and a participant progressing much later do not provide the same information. Time-to-event methods retain that temporal information.
Why use Kaplan-Meier estimation?
Kaplan-Meier estimation is designed for settings in which some participants may remain event-free at the end of their observed follow-up. Instead of requiring every participant to experience progression or death, it uses the information available up to each participant's event or censoring time.
What would a hazard ratio for PFS mean?
A PFS hazard ratio below 1 would indicate a lower estimated instantaneous rate of progression or death in the palbociclib-containing group relative to the endocrine-therapy group under the fitted model. It would not mean that the same percentage of participants avoid progression or that every patient experiences that relative reduction.
Why does RECIST matter statistically?
The event time in PFS depends on identifying objective tumor progression. RECIST v.1.1 provides the assessment framework specified by the registry, making the definition of the event more standardized than an unspecified clinical judgment of progression.
What does censoring mean?
Censoring occurs when the exact event time is not observed during the period of usable follow-up. A participant who remains progression-free through the last observed assessment contributes information up to that time, rather than being treated as though the participant had experienced progression at the end of follow-up.
Why is a p-value not enough to describe PFS?
A p-value addresses evidence against a specified null hypothesis under the statistical testing framework. It does not describe the magnitude of a treatment effect. A complete PFS analysis would ordinarily consider an effect estimate, its confidence interval, the survival distributions or clinically meaningful time points, and the underlying event and censoring patterns.
8. Understanding the Primary Endpoint
PFS in PALMIRA is defined from randomization until objective tumor progression or death. This means that death is an event even if objective tumor progression has not been documented first.
The endpoint therefore captures disease-control duration through two clinically important pathways. A statistical comparison must preserve that composite event definition when estimating treatment effects.
If a median PFS were reported, it would represent the time at which the estimated PFS probability crosses 50%. It would describe the distribution of event times but would not by itself describe the complete treatment effect over follow-up.
If a hazard ratio were reported, it would provide a relative model-based comparison of the instantaneous rate of progression or death. Its interpretation would depend on the fitted model and, for a conventional Cox analysis, the proportional-hazards assumption.
A confidence interval around a treatment-effect estimate describes statistical uncertainty under the relevant estimation framework. A narrow interval generally provides more precision than a wide interval, while the interval itself does not describe the range of outcomes that individual patients will experience.
9. Analysis Population and Randomization
The registry establishes that PALMIRA was randomized, with 198 participants enrolled into two parallel arms. It does not provide arm-specific enrollment counts in the record summarized here.
| Design feature | Registered information | Statistical significance |
|---|---|---|
| Randomization | RANDOMIZED | Creates the principal framework for comparing outcomes between treatment assignments. |
| Parallel design | PARALLEL | Participants remain assigned to their randomized treatment pathway rather than forming a crossover sequence. |
| Masking | NONE | The study is not described as masked, which can be relevant when outcome assessment involves clinical judgment. |
| Enrollment | 198 | Defines the registered overall study population available for the randomized comparison. |
The absence of masking does not automatically determine the direction or size of an outcome difference. Its importance depends on the endpoint and on how progression assessments are conducted and documented.
10. Missing Data, Censoring, and Follow-Up
The registry defines the primary PFS time frame as baseline up to 29 months. Because PFS is a time-to-event endpoint, incomplete follow-up is handled differently from a missing value in a conventional continuous endpoint.
Censoring
A participant who has not experienced progression or death during observed follow-up may contribute information up to the last appropriate observation.
Event definition
Both objective tumor progression and death are qualifying PFS events under the registered definition.
Follow-up horizon
The registered primary endpoint has a time frame of baseline up to 29 months.
Imputation
No specific missing-data or imputation strategy is reported in the available registry information.
For a time-to-event analysis, the statistical treatment of censoring is therefore a central component of the analysis rather than a secondary data-cleaning step. The assumptions governing censoring can affect estimated PFS curves and treatment-effect estimates.
11. Statistical Issues Specific to an Unmasked PFS Trial
PALMIRA is registered as having no masking. For a PFS endpoint based on objective tumor progression assessed by RECIST v.1.1, the statistical consequences of an unmasked design depend on the process used to obtain and classify tumor assessments.
| Issue | Why it matters |
|---|---|
| Knowledge of treatment assignment | Participants and investigators may know the assigned treatment, which can influence clinical management and follow-up processes. |
| Objective progression criteria | RECIST v.1.1 supplies a standardized framework for determining objective tumor progression. |
| Timing of assessments | PFS depends on when progression is detected, so differences in assessment timing can influence observed event times. |
| Death as an event | Death remains part of the primary endpoint regardless of whether objective progression was documented first. |
These considerations do not establish bias in either direction. They identify aspects of trial conduct that are relevant when interpreting a time-to-event endpoint in an unmasked randomized design.
12. Non-Inferiority, Factorial, Bayesian, and Interim-Analysis Considerations
The registered information does not identify PALMIRA as a non-inferiority trial, factorial trial, or Bayesian analysis. It also does not describe an interim analysis or an alpha-spending strategy.
| Design topic | Registered information |
|---|---|
| Non-inferiority margin | Not reported in the available registry information. |
| Factorial design | The design model is registered as PARALLEL with two arms. |
| Bayesian methods | Not reported. |
| Interim analysis | Not reported. |
| Alpha spending | Not reported. |
| Multiplicity strategy | Not reported. |
This distinction is important. Statistical methods should be attributed to the design when they are documented; when they are not documented, a conventional method can be described as an analytical framework rather than presented as the registered method of the trial.
13. Results Status
Accordingly, the statistical interpretation of PALMIRA at the registry level centers on the design and endpoint definition rather than an observed treatment-effect estimate.
14. Why This Trial Matters Statistically
PALMIRA is a useful teaching example because its primary endpoint illustrates several foundational principles of clinical-trial statistics without reducing the analysis to a single number.
| Concept | How it appears in PALMIRA |
|---|---|
| Randomization | The trial uses randomized allocation to two treatment arms. |
| Parallel-group design | The registered design model is PARALLEL. |
| Phase 2 evaluation | The trial is registered as phase 2 with a treatment purpose. |
| Time-to-event endpoint | PFS measures time from randomization to objective progression or death. |
| RECIST assessment | Objective tumor progression is assessed using RECIST criteria v.1.1. |
| Censoring | Time-to-event methodology can incorporate participants whose event has not been observed during follow-up. |
| Hazard ratio | A Cox model is a conventional framework for estimating relative PFS event rates. |
| Confidence interval | Confidence intervals would quantify uncertainty around an estimated treatment effect. |
| Unmasked design | The registry identifies masking as NONE, making assessment processes relevant to interpretation. |
15. Important Limitations and Interpretation Issues
- No posted statistical analysis: the ClinicalTrials.gov record does not provide a formal statistical analysis for the primary PFS endpoint.
- No posted treatment-effect estimate: there is no registry-reported hazard ratio, confidence interval, p-value, median PFS, or PFS event count in the available record.
- No arm-specific enrollment counts: the record identifies 198 participants overall and two arms but does not provide arm-specific sample sizes in the information available here.
- Unmasked design: the registry describes the trial as having no masking. The implications depend on how treatment knowledge interacts with clinical management and progression assessment.
- Time-to-event assumptions: Kaplan-Meier and Cox analyses require appropriate handling of censoring, and Cox interpretation additionally depends on the proportional-hazards framework when that model is used.
- Progression assessment: PFS depends on the timing and classification of objective tumor progression according to RECIST v.1.1.
- Missing-data strategy: the available registry information does not specify an imputation or missing-data strategy.
- Multiplicity: the available registry information does not specify a multiplicity-control strategy.
- Generalizability: the registered population is specifically described as pre- and post-menopausal women with HR-positive/HER2-negative advanced breast cancer, so conclusions from the trial population should not automatically be extended beyond that population.
16. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The registered primary endpoint is a randomized-group comparison of progression-free survival. A conventional analysis would estimate time-to-event distributions and a relative treatment effect while accounting for censoring.
Clinical interpretation
The clinical question concerns whether continuing palbociclib with second-line endocrine therapy changes the period from randomization until objective tumor progression or death relative to endocrine therapy.
The distinction matters because a clinical question is broader than a single statistical test. PFS is intended to characterize the timing of disease progression or death, while the statistical analysis provides a framework for quantifying differences between randomized treatment groups.
17. Reading a Future PFS Result Correctly
If a formal PFS analysis becomes available, several quantities should be considered together rather than in isolation.
| Quantity | What it tells the reader | What it does not tell the reader by itself |
|---|---|---|
| Hazard ratio | Relative difference in estimated instantaneous event rates under the fitted model. | The percentage of patients who benefit or the absolute difference in PFS at a particular time. |
| 95% confidence interval | Statistical uncertainty around the effect estimate. | The range of outcomes that individual patients will experience. |
| Median PFS | The time corresponding to an estimated PFS probability of 50%, when the median is estimable. | The complete shape of the PFS distribution or the relative treatment effect over all follow-up. |
| Kaplan-Meier curve | The estimated PFS probability over time and the timing of events and censoring. | A direct causal explanation for every separation or convergence seen in the curve. |
| P-value | Evidence against a specified null hypothesis under the stated testing framework. | Effect size, clinical importance, or probability that the treatment hypothesis is true. |
This framework prevents a common statistical mistake: treating statistical significance, effect magnitude, precision, and clinical meaning as though they were interchangeable concepts.
18. A Statistical Workflow for PALMIRA
The workflow begins with the endpoint definition rather than with a statistical test. That order is deliberate: the validity of a PFS analysis depends first on correctly defining the event, time origin, follow-up, and censoring rules.
The comparison can be expressed using survival curves, a hazard ratio, differences at clinically relevant time points, or other prespecified estimands. Each measure answers a somewhat different question.
19. Sources
- ClinicalTrials.gov: PALMIRA, NCT03809988.
- PubMed: PALMIRA publication record.
Continue through the Clinical Biostats knowledge graph
Clinical trial endpoints can be studied in greater depth by connecting trial design, survival analysis, statistical estimation, and interpretation.
20. Record Summary
PALMIRA is a completed randomized phase 2 parallel-group trial with 198 enrolled participants and two treatment arms. The registered primary endpoint is progression-free survival, defined as the period from randomization until objective tumor progression or death, with objective progression assessed according to RECIST criteria v.1.1 and a time frame from baseline up to 29 months.
Statistically, the trial is primarily a time-to-event problem. The appropriate analytical framework focuses on the PFS event definition, time origin, censoring, estimation of the PFS distribution, comparison of randomized groups, and quantification of uncertainty around any treatment-effect estimate. Kaplan-Meier estimation, log-rank comparison, and Cox proportional-hazards modeling are standard approaches for this type of endpoint, although the registry information available here does not identify a posted formal analysis using those methods.